Company Overview

U.S. Stem Cell, Inc. (OTC: USRM) is a biotechnology and regenerative medicine company focused on stem cell processing, cell-based therapeutics, and regenerative medicine services. The company has historically operated in the regenerative healthcare sector through a combination of stem cell banking, physician training, laboratory services, and the development of adipose-derived stem cell technologies. Public filings and company disclosures indicate that its activities have included stem cell collection and processing systems, clinical support services, and physician-focused regenerative medicine programs. The company has also been associated with direct-to-consumer regenerative treatment offerings through affiliated clinical operations.

The company evolved from Bioheart, Inc., a cardiac cell therapy developer founded in the early 2000s, before rebranding to U.S. Stem Cell, Inc. as it broadened its focus beyond cardiovascular therapies into regenerative medicine and stem cell applications. Historically, the company positioned itself around minimally invasive autologous stem cell procedures using adipose tissue-derived cells. Its strategic positioning centered on physician education, proprietary processing systems, and regenerative medicine infrastructure, though the company has faced significant regulatory scrutiny and legal challenges related to certain stem cell treatment activities. Information regarding current operational scale and commercial traction is limited in recent public disclosures, and some operational details are inconclusive based on available public sources.

Business Operations

U.S. Stem Cell, Inc. historically organized operations around regenerative medicine technologies, stem cell banking, laboratory processing, and clinical support activities. Key business activities included the commercialization of stem cell processing equipment, physician training programs, and laboratory services designed to isolate and process autologous stem cells derived from adipose tissue. The company also operated or supported regenerative medicine clinics through affiliated entities and licensing arrangements. Revenue historically came from procedure-related services, equipment sales, physician training, and laboratory processing fees.

The company’s operations were primarily concentrated in the United States, particularly in Florida, where its headquarters and laboratory operations were located. Public filings reference subsidiaries including U.S. Stem Cell Clinic, LLC, U.S. Stem Cell Training, Inc., and U.S. Stem Cell Laboratories, Inc. The company also promoted proprietary or internally developed stem cell processing methodologies and related equipment platforms. Regulatory filings and federal court records indicate that certain clinical activities became the subject of enforcement actions by the U.S. Food and Drug Administration (FDA), resulting in litigation and operational impacts. Data regarding the current status of several subsidiaries and commercial programs is inconclusive based on available public sources.

Strategic Position & Investments

U.S. Stem Cell’s strategic direction historically focused on expanding access to regenerative medicine procedures through physician partnerships, training initiatives, and laboratory infrastructure. The company sought to position itself within the broader regenerative medicine and cell therapy market by emphasizing autologous stem cell applications that did not rely on embryonic stem cells. Growth initiatives included physician certification programs, expansion of stem cell banking services, and development of treatment protocols intended for orthopedic, neurological, and degenerative conditions.

The company’s historical investments included laboratory facilities, stem cell processing technologies, and affiliated clinic operations. Its evolution from Bioheart, Inc. reflected a broader shift from cardiovascular cell therapy research toward commercial regenerative medicine services. Public disclosures also indicate prior involvement in intellectual property and proprietary processing systems related to adipose-derived stem cell extraction and handling. However, the long-term commercialization and scalability of these technologies remain uncertain due to regulatory actions, litigation, and limited publicly available financial updates in recent years.

Geographic Footprint

U.S. Stem Cell, Inc. has primarily operated within the United States, with its principal executive offices historically located in Sunrise, Florida. The company’s operational footprint centered on domestic physician networks, regenerative medicine clinics, and laboratory facilities supporting stem cell processing and training activities. Public materials also referenced outreach to physicians and patients from outside the United States seeking regenerative medicine procedures.

Although the company promoted international visibility within the regenerative medicine community, publicly verifiable evidence of substantial long-term international operations or major overseas subsidiaries is limited. Its influence outside the United States appeared to be primarily educational, promotional, or patient-driven rather than based on large-scale international infrastructure. Data regarding active international operations or investments is inconclusive based on available public sources.

Leadership & Governance

U.S. Stem Cell, Inc.’s leadership historically included executives associated with both regenerative medicine commercialization and the company’s earlier operations as Bioheart, Inc. Public filings identify Kristin Comella as a prominent executive and scientific figure connected to the company’s regenerative medicine initiatives and training activities. Leadership strategy emphasized physician education, commercialization of stem cell technologies, and expansion of regenerative treatment accessibility.

Key executives identified in public filings and company disclosures include:

• Kristin Comella – Chief Scientific Officer
• Mike Tomas – Former Chief Executive Officer
• Thomas Ichim – Former Board Member and scientific advisor
• Rafael Gonzalez – Executive associated with clinical operations and physician training activities

Governance and operational oversight were significantly influenced by regulatory and legal developments involving FDA enforcement actions related to stem cell procedures. Publicly available information on the company’s current executive structure and board composition is limited, and some leadership details are inconclusive based on available public sources.